- Medicenna Therapeutics Corp (NASDAQ:MDNA) announced new clinical data from the Phase 1/2 ABILITY study of MDNA11.
- The data provide preliminary evidence of MDNA11’s single-agent anti-cancer activity in patients with advanced solid tumors who have been unresponsive to other treatments.
- MDNA11 treatment in Cohort 4 (comprised of two step-up doses of 30 µg/kg followed by fixed doses of 60 µg/kg every two weeks) was not associated with any dose-limiting toxicities.
- The Safety Review Committee has approved dose escalation for Cohort 5 to the 90 µg/kg dose every two weeks following two priming doses at 30 µg/kg.
- Significant increases in eosinophil count from baseline were not observed with MDNA11 treatment.
- Four of ten evaluable patients achieved tumor control, including two patients at the 10 µg/kg dose (sarcoma and metastatic melanoma), one sarcoma patient at the 30 µg/kg dose, and one pancreatic cancer patient in Cohort 4 receiving the 60 µg/kg dose.
- The first imaging scans in the remaining four patients enrolled at the 60 µg/kg dose are expected in September.
- Treatment with MDNA11 leads to multi-fold increases in anti-cancer immune cells without stimulation of cells that cause immunosuppression and toxicity.
- Price Action: MDNA shares are up 12.20% at $1.56 during the market session on the last check Wednesday.
Tesla’s Q1 US Sales Mainly Held Back By Very Model That Saved It From Bankruptcy Years Ago
As per the research company, Tesla sold 140,187 electric vehicles in the U.S. last quarter, marking a 13.3% drop from the 161,630 vehicles sold in the corresponding quarter of 2023.
